Unlock instant, AI-driven research and patent intelligence for your innovation.

A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect

A pharmaceutical and hydroxyl technology, applied in the direction of drug combination, organic active ingredients, nervous system diseases, etc., can solve the problem of high mortality of diabetic patients

Inactive Publication Date: 2012-12-12
N GENE RES LAB
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Also, people with diabetes have a higher mortality rate due to a higher risk of cardiovascular disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect
  • A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect
  • A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0169] The effect of BGP-15 on the weight gain of rats induced by olanzapine

[0170] Groups of female Wistar rats were treated with vehicle (control group) and test compound for 28 days. Six animals per group were fed ad libitum with normal laboratory chow and tap water. Test compounds were administered orally twice daily at 8:00 am and 6:00 pm. Among them, the antipsychotic drug olanzapine was administered at a dose of 1 mg / kg to induce weight gain. The dose of BGP-15 was 10 mg / kg, one group was administered alone, and the other group was co-administered with olanzapine. Oral antidiabetic drugs metformin (100 mg / kg) and rosiglitazone (3 mg / kg) were used as control compounds, and one group was administered alone, and the other group was co-administered with olanzapine. The average initial body weight of the experimental rats was 171 g. The body weights of the animals in each group at the end of the experiment on day 28 are shown in Table 1.

[0171] Table 1

[0172] ...

Embodiment 2

[0175] Effect of BGP-15 on body weight gain in mice induced by olanzapine or clozapine

[0176] Groups of female NMRI mice were orally treated with vehicle (control group) and test compound for 15 days. Ten animals per group were fed ad libitum with regular laboratory chow and tap water. Treat daily between 5pm and 6pm, slightly before dark, which is also the main feeding time of the day. To induce weight gain, the antineurotic drug olanzapine was administered at a dose of 0.5 mg / kg, and the antipsychotic drug clozapine was administered at a dose of 1 mg / kg. The dosage of BGP-15 was 10 mg / kg, one group was administered alone, and the other two groups were administered together with olanzapine and clozapine respectively. The body weight of the experimental animals was recorded twice a week. The body weight changes of the animals between day 1 and day 15 are shown in Table 2.

[0177] Table 2

[0178]

therapy group

Weight gain (group average

v...

Embodiment 3

[0182] Effect of BGP-15 on body weight gain induced by risperidone in rats

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The side effect leading to overweight or obesity in medication with a known antipsychotic, antidepressant or antiepileptic drug is reduced by the administration of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition with antipsychotic, antidepressant or antiepileptic activity and reduced side effects, and O-(3-piperidino-2-hydroxyl-1-propyl)-nicotine amidoxime Use of a pharmaceutically acceptable acid addition salt thereof in the preparation of a medicament suitable for preventing or alleviating the side effects of overweight or obesity caused by known antipsychotic drugs, antidepressants or antiepileptic drugs. Background of the invention [0002] Antipsychotic drugs are used to treat mental illness, especially schizophrenia, while antidepressants are used to reduce symptoms of depression. Antiepileptic drugs prevent or reduce the severity and frequency of seizures in all types of epilepsy. Many patients who take antipsychotic drugs, such as olanzapine or clozapine, experience bulimia because the drug interferes with the regulation of food intake. Therefore, the treatment of psychiatric disorders o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4545A61K31/19A61K31/40A61K31/519A61K31/551A61K31/554A61P25/08A61P25/18A61P25/24
Inventor P·利特纳提纳吉J·罗斯Z·西尔瓦希K·托里M·布朗斯汀K·塔卡克斯L·维格J·曼德尔B·苏梅吉S·伯纳斯A·克罗尼克斯G·巴洛戈J·厄戈里
Owner N GENE RES LAB